|
| Authors | Year | Country | Study design | Type of BRPCa patients evaluated | No. of BRPCa patients performing [18F] PSMA-1007 PET/CT or PET/MRI | Mean/median age (years) | Gleason score | Mean/median PSA values before PET (ng/mL) | Mean/median PSA doubling time before PET (months) |
|
| Ahmadi Bidakhvidi et al. [22] | 2021 | Belgium | Retrospective monocentric | Patients with BRPCa previously treated with RP (78%), RT (8.8%), ADT (7.3%), brachytherapy (5.1%), or HIFU (0.7%). Adjuvant RT in 22% of cases. Prior ADT in 61% of cases; ongoing ADT in 24% of cases | 137 (175 scans) | Median (range): 70 (46–88)
Mean ± SD: 69 ± 8.8 | 5: 0.7%
6: 6.6%
7: 49%
8: 24%
9: 19%
NA: 0.7% | Median (range): 1.6 (0.07–429)
Mean ± SD: 11.1 ± 47.5 | Median (range): 6.7 (0.8–96.9)
Mean ± SD: 9.5 ± 10.1 |
|
| Dietlein et al. [23] | 2020 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP or RT | 23 | Mean ± SD: 67.2 ± 7.8 | 6: 9%
7: 48%
8: 13%%
9: 17%
NA: 13% | Median (range): 1.5 (0.3–27.7)
Mean ± SD: 2.9 ± 5.7 | NA |
|
| Giesel et al. [24] | 2018 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP (83%) or RT (67%) | 12 | Median (range): 70 (54–79)
Mean ± SD: 68.2 ± 7.7 | 6: 8%
7: 50%
8: 25%
9: 17% | Median (range): 0.6 (0.08–6.5)
Mean ± SD: 1.9 ± 2.2 | NA |
|
| Giesel et al. [25] | 2019 | Germany and Chile | Retrospective multicentric | Patients with BRPCa previously treated with RP (26.7%), RP + ADT (29.5%) or RP + RT (43.8%); 23.9% of patients had received first-line ADT within the last 6 months before PET | 251 | Median (range): 70 (48–86) | ≤6: 5.2%
7: 49.8%
≥8: 33.1%
NA: 11.2% | Median (range) 1.2 (0.2–228) | NA |
|
| Liu et al. [26] | 2020 | China | Retrospective monocentric | Patients with BRPCa after curative therapy (77.3%) or after ADT (22.7%) as initial treatment. Ongoing ADT before PET/MRI in 59.1% of cases | 22 | Median (IQR): 70.5 (63–75.8) | NA | Median (IQR): 2.0 (0.9–4.7) | Median (IQR): 2.1 (1.5–5.6) |
|
| Morawitz et al. [27] | 2021 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP | 23 | Mean ± SD: 71 ± 8.5 | NA | Median (range): 1.5 (0.2–7)
Mean ± SD: 1.96 ± 1.64 | NA |
|
| Rahbar et al. [28] | 2018 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP or RT | 28 | Mean ± SD: 68.7 ± 8.1 | 7: 20%
8: 15%
9: 22.5%
10: 2.5%
NA: 40% | NA | NA |
|
| Rahbar et al. [29] | 2018 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP (92%), RT (45%), ADT (27%), RP + RT (38%), or RP + RT + ADT (10%) | 100 | Median (range): 70.44 (47.36–85.82)
Mean ± SD: 68.75 ± 7.6 | Median (range): 7 (5–10)
Mean ± SD: 7.5 ± 1.01 | Median (range): 1.34 (0.04–41.3)
Mean ± SD: 3.36 ± 6.11 | NA |
|
| Rauscher et al. [30] | 2020 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP (76.5%) or RP + ADT (23.5%) | 102 | Median (range): 71 (51–84) | 6-7: 62%
7-8: 38% | Median (range): 0.87 (0.2–13.59) | NA |
|
| Sachpekidis et al. [31] | 2020 | Germany | Retrospective monocentric | Patients with BRPCa previously treated with RP (52.9%), RP + RT (35.3%), hyperthermia + ADT (5.8%), or RP + RT + ADT (5.8%). No treatment at the time of scanning | 17 | Median (range): 69 (48–77)
Mean ± SD: 67.5 ± 7.3 | 6: 6%
7: 59%
8: 12%
10: 6%
NA: 17% | Median (range): 0.76 (0.14–4.49)
Mean ± SD: 1.27 ± 1.27 | NA |
|
| Sprute et al. [32] | 2021 | Germany, Chile, and Japan | Retrospective multicentric | Patients with BRPCa previously treated with RP | 9 | Median (range): 69.5 (48–78) | 6: 3%
7: 60%
8: 7%
9: 30% | Median (range): 1.8 (0.47–4.7) | NA |
|
| Watabe et al. [33] | 2021 | Japan | Prospective monocentric | Patients with BRPCa previously treated with RP (39.3%), RT (32.1%) or RP + RT (28.6%) | 28 | Median (range): 67.5 (51–79) | 6: 18%
7: 43%
8: 14%
9: 25% | Median (range): 2.39 (0.12–39.78) | NA |
|
| Witkowska-Patena et al. [34] | 2019 | Poland | Prospective monocentric | Patients with BRPCa previously treated with RP (80%) or RT (20%); adjuvant RT in 42.5% of cases; 25% of the patients received ADT (none of them within 6 months prior to the study) | 40 | Median (range): 68 (58–83)
Mean ± SD: 69 ± 7 | Median (range): 7 (5–9)
Mean ± SD: 7.1 ± 1 | Median (range): 0.7 (0.01–2.0)
Mean ± SD: 0.77 ± 0.61 | NA |
|
| Witkowska-Patena et al. [35] | 2020 | Poland | Prospective monocentric | Patients with BRPCa previously treated with RP (80%) or RT (20%); adjuvant RT in 40% of cases; 25% of the patients received ADT (none of them within 6 months prior to the study) | 40 | Median (range): 67.5 (58–83)
Mean ± SD: 68.6 ± 6.5 | Median (range): 7 (4-9)
Mean ± SD: 6.9 ± 1.2 | Median (range): 0.65 (0.008–2.0)
Mean ± SD: 0.75 ± 0.6 | NA |
|
| Wondergem et al. [36] | 2021 | Netherlands | Retrospective monocentric | Patients with BRPCa previously treated with RP (33.3%), RT (57.1%), or brachytherapy (9.5%); ADT after RT in 9.5% of cases | 21 | NA | NA | Median (range): 2.4 (0.4–7.8) | NA |
|
